Finding the Path in Idiopathic Hypersomnia:

Program Description

Idiopathic hypersomnia (IH) is a chronic central disorder of hypersomnolence that imposes profound disease burdens and health consequences for patients. Diagnosis and management remain challenging for clinicians due to nonspecific symptoms and poorly understood pathophysiology. The IH Patient Journey™ activity will immerse learners in a longitudinal, real-world case that reflects the lived experience of a patient with IH. Through integrated patient narratives and expert clinician commentary, participants will explore diagnostic hurdles, management strategies, and shared decision-making opportunities that will aim to enhance practice and improve patient care.

Target Audience

This activity will provide continuing medical education (CME) that addresses identified knowledge and practice gaps among sleep medicine, pulmonology, neurology, and psychiatry specialist physicians (MDs/DOs), nurse practitioners (NPs), and physician associates (PAs) related to the diagnosis and treatment of idiopathic hypersomnia (IH).

Educational Objectives 

• Describe the range of biopsychosocial burdens faced by patients with idiopathic hypersomnia, including cardiovascular risks
• Identify patients with idiopathic hypersomnia promptly based on symptoms, sleep evaluations, and testing to rule out other disorders
• Discuss recent clinical trial results and practical prescribing parameters for pharmacotherapy-based treatment of idiopathic hypersomnia
• Tailor multimodal therapeutic regimens for idiopathic hypersomnia that address symptoms, comorbidities, therapeutic responses, and shared decision-making

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The ANCC’s Commission on Accreditation recognizes educational activities that are approved for AMA PRA Category 1 Credits™ by providers who are accredited by the ACCME to award credit to learners. This reciprocity agreement allows nurses and nurse practitioners to use AMA PRA Category 1 Credits™ as approved ANCC contact hours for license renewal. 

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Integritas Contact Information

For more information about the approval of this program, please contact Integritas at info@exchangecme.com. 

Instructions to Receive Credit

In order to receive credit for this activity, the participant must:

1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
2. Complete the Preactivity Questions.
3. Review the activity content.
4. Achieve a grade of at least 70% on the Postactivity Test Questions and complete the Evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.  

All relevant financial relationships have been mitigated. 

The faculty have the following relevant financial relationships with ineligible companies:

Anne Marie Morse, DO, FAASM:

• Investigator, Consultant, Speaker, Advisory board: Alkermes, Apnimed, Avadel Pharmaceuticals, Axsome, Eisai, Harmony Biosciences, Jazz Pharmaceuticals, Lilly, Lundbeck, Noble Pharmaceuticals, Novartis, and Takeda Pharmaceutical Co.

• Advisory Board: Neura Health, Open Evidence and Floraworks.

• Grant funding: Coverys Foundation, Geisinger Health Plan, Harmony Biosciences, Jazz Pharmaceuticals, Inc., ResMed Foundation, UCB Pharmaceuticals

Haley Wall

• Nothing to disclose

The Integritas planners and managers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.